Evogene Ltd. EVGN.TA Stock
Evogene Ltd. Price Chart
Evogene Ltd. EVGN.TA Financial and Trading Overview
| Evogene Ltd. stock price | 277.6 ILA |
| Previous Close | 243.1 ILA |
| Open | 266 ILA |
| Bid | 221.6 ILA x 286700 |
| Ask | 221.7 ILA x 100 |
| Day's Range | 266 - 273.9 ILA |
| 52 Week Range | 204.3 - 428.5 ILA |
| Volume | 261.34K ILA |
| Avg. Volume | 42.16K ILA |
| Market Cap | 113.24M ILA |
| Beta (5Y Monthly) | 0.827397 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.95 ILA |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4 ILA |
EVGN.TA Valuation Measures
| Enterprise Value | 80.42M ILA |
| Trailing P/E | N/A |
| Forward P/E | -17.00625 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 54.46751 |
| Price/Book (mrq) | 512.4294 |
| Enterprise Value/Revenue | 38.684 |
| Enterprise Value/EBITDA | -3.37 |
Trading Information
Evogene Ltd. Stock Price History
| Beta (5Y Monthly) | 0.827397 |
| 52-Week Change | 1.12% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 428.5 ILA |
| 52 Week Low | 204.3 ILA |
| 50-Day Moving Average | 223.97 ILA |
| 200-Day Moving Average | 259.62 ILA |
EVGN.TA Share Statistics
| Avg. Volume (3 month) | 42.16K ILA |
| Avg. Daily Volume (10-Days) | 73.27K ILA |
| Shares Outstanding | 41.62M |
| Float | 40.78M |
| Short Ratio | N/A |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 3.38% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:2 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1235.30% |
| Gross Margin | 48.62% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.58% |
| Return on Equity (ttm) | -66.61% |
Income Statement
| Revenue (ttm) | 2.08M ILA |
| Revenue Per Share (ttm) | 0.05 ILA |
| Quarterly Revenue Growth (yoy) | 170.50% |
| Gross Profit (ttm) | 766K ILA |
| EBITDA | -23868000 ILA |
| Net Income Avi to Common (ttm) | -24634000 ILA |
| Diluted EPS (ttm) | -2.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 28.8M ILA |
| Total Cash Per Share (mrq) | 0.69 ILA |
| Total Debt (mrq) | 1.64M ILA |
| Total Debt/Equity (mrq) | 5.77 ILA |
| Current Ratio (mrq) | 5.864 |
| Book Value Per Share (mrq) | 0.531 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22215000 ILA |
| Levered Free Cash Flow (ttm) | -13814250 ILA |
Profile of Evogene Ltd.
| Country | Israel |
| State | N/A |
| City | Rehovot |
| Address | 13 Gad Feinstein Street |
| ZIP | 7414002 |
| Phone | 972 8 931 1900 |
| Website | https://www.evogene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 137 |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Q&A For Evogene Ltd. Stock
What is a current EVGN.TA stock price?
Evogene Ltd. EVGN.TA stock price today per share is 277.6 ILA.
How to purchase Evogene Ltd. stock?
You can buy EVGN.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Evogene Ltd.?
The stock symbol or ticker of Evogene Ltd. is EVGN.TA.
Which industry does the Evogene Ltd. company belong to?
The Evogene Ltd. industry is Biotechnology.
How many shares does Evogene Ltd. have in circulation?
The max supply of Evogene Ltd. shares is 520.64K.
What is Evogene Ltd. Price to Earnings Ratio (PE Ratio)?
Evogene Ltd. PE Ratio is now.
What was Evogene Ltd. earnings per share over the trailing 12 months (TTM)?
Evogene Ltd. EPS is -1.95 ILA over the trailing 12 months.
Which sector does the Evogene Ltd. company belong to?
The Evogene Ltd. sector is Healthcare.